دورية أكاديمية
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer
| العنوان: | Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer |
|---|---|
| المؤلفون: | Dieci M. V., Conte P., Bisagni G., Bartolini S., Frassoldati A., Generali D., Piacentini F., Griguolo G., Tagliafico E., Braso Maristany F., Chic N., Pare L., Miglietta F., Vicini R., D'Amico R., Balduzzi S., Prat A., Guarneri V. |
| المساهمون: | Dieci, M. V., Conte, P., Bisagni, G., Bartolini, S., Frassoldati, A., Generali, D., Piacentini, F., Griguolo, G., Tagliafico, E., Braso Maristany, F., Chic, N., Pare, L., Miglietta, F., Vicini, R., D'Amico, R., Balduzzi, S., Prat, A., Guarneri, V. |
| سنة النشر: | 2024 |
| المجموعة: | Archivio della ricerca dell'Università di Modena e Reggio Emilia (Unimore: IRIS) |
| الوصف: | Background: Even with contemporary treatment strategies, more than 10% of HER2-positive early stage breast cancer patients may experience distant metastasis as first event during follow-up. Tools for predicting unique patterns of metastatic spread are needed to plan personalized surveillance. We evaluated how molecular heterogeneity affects the pattern of distant relapse in HER2-positive breast cancer. Methods: A total of 677 HER2-positive stage I-III breast cancer patients from ShortHER trial, Cher-LOB trial, and 2 institutional cohorts were included. PAM50 molecular subtypes and research-based HER2DX scores were evaluated. The cumulative incidence of distant relapse as the first event (any site and site specific) was evaluated using competing risk analysis. Median follow-up was 8.4 years. Tests of statistical significance are 2-sided. Results: Stage III and high HER2DX risk score identified patients at the highest risk of distant relapse as first event (10-year incidence 24.5% and 19.7%, respectively). Intrinsic molecular subtypes were associated with specific patterns of metastatic spread: compared with other subtypes, HER2-enriched tumors were more prone to develop brain metastases (10-year incidence 3.8% vs 0.6%, P =. 005), basal-like tumors were associated with an increased risk of lung metastases (10-year incidence 11.1% vs 2.6%, P =. 001), and luminal tumors developed more frequently bone-only metastases (10-year incidence 5.1% vs 2.0%, P =. 042). When added to stage or HER2DX risk score in competing risk regression models, intrinsic subtype maintained an independent association with site-specific metastases. Conclusions: The integration of intrinsic molecular subtypes with stage or HER2DX risk score predicts site-specific metastatic risk in HER2-positive breast cancer, with potential implications for personalized surveillance and clinical trials aimed at preventing site-specific recurrence. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/37676829; volume:116; issue:1; firstpage:69; lastpage:80; journal:JOURNAL OF THE NATIONAL CANCER INSTITUTE; https://hdl.handle.net/11380/1334667Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85182091255 |
| DOI: | 10.1093/jnci/djad179 |
| الإتاحة: | https://doi.org/10.1093/jnci/djad179Test https://hdl.handle.net/11380/1334667Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.13DA32A6 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/jnci/djad179 |
|---|